Thymoma and Thymic Carcinoma
The thymus is a lymphoid organ located in the anterior mediastinum. In early life, the thymus is responsible for the development and maturation of cell-mediated immunological functions. The thymus is composed predominantly of epithelial cells and lymphocytes. Precursor cells migrate to the thymus and differentiate into lymphocytes. Most of these lymphocytes are destroyed, with the remainder of these cells migrating to tissues to become T lymphocytes. The thymus gland is located behind the sternum in front of the great vessels (see Media files 1-2). The thymus gland reaches its maximum weight at puberty and undergoes involution thereafter. Thymoma, the most common neoplasm of the anterior mediastinum, originates within the epithelial cells of the thymus.
History of the Procedure
A relationship between myasthenia gravis (MG) and thymomas was determined incidentally in 1939 when Blalock and coworkers reported the first excision of a thymic cyst in a 19-year-old girl with MG. This patient achieved long-term remission; therefore, thymectomy became the definitive therapy for treatment of generalized MG.
No clear histologic distinction between benign and malignant thymomas exists. The propensity of a thymoma to be malignant is determined by the invasiveness of the thymoma. Malignant thymomas can invade the vasculature, lymphatics, and adjacent structures within the mediastinum. The 15-year survival rate of a person with an invasive thymoma is 12.5%, and it is 47% for a person with a noninvasive thymoma. Death usually occurs from cardiac tamponade or other cardiorespiratory complications.
Thymoma, the most common neoplasm of the anterior mediastinum, accounts for 20-25% of all mediastinal tumors and 50% of anterior mediastinal masses.
The etiology of thymomas has not been elucidated; however, it has been associated with various systemic syndromes. As many as 30-40% of patients who have a thymoma experience symptoms suggestive of MG. An additional 5% of patients who have a thymoma have other systemic syndromes, including red cell aplasia, dermatomyositis, systemic lupus erythematous, Cushing syndrome, and syndrome of inappropriate antidiuretic hormone secretion.
Peak incidence of thymoma occurs in the fourth to fifth decade of life; mean age of patients is 52 years. No sexual predilection exists. Although development of a thymoma in childhood is rare, children are more likely than adults to have symptoms. Several explanations for the prevalence of symptoms in children have been proposed, including the following: (1) children are more likely to have malignancy, (2) lesions are more likely to cause symptoms by compression or invasion in the smaller thoracic cavity of a child, and (3) the most common location for mediastinal tumors in children is near the trachea, resulting in respiratory symptoms.
Four cases of patients who presented with severe chest pain secondary to infarction or hemorrhage of the tumor have recently been reported. Cases of invasion into the superior vena cava resulting in venous obstruction have also been reported. The clinician should be aware of these rare presentations of a thymoma.
Phone Numbers Reach Us -
India & International : +91 9371770341
Of patients with a thymoma, one third to one half are asymptomatic, and one third of patients present with local symptoms related to the tumor encroaching on surrounding structures. These patients may present with cough, chest pain, superior vena cava syndrome, dysphagia, and hoarseness if the recurrent laryngeal nerve is involved. One third of cases are found incidentally on radiographic examinations during a workup for MG.
The thymus gland is located behind the sternum in front of the great vessels and the pericardium (see Media files 1-2). The gland can extend laterally to the phrenic nerves. The main blood supply is from the internal thoracic arteries; however, the thymus gland also is supplied with blood by the inferior thyroid and pericardiophrenic arteries.
If the thymoma invades both phrenic nerves, do not resect either nerve; only debulk the area.
Treatment Medical TherapyChemotherapy
A few reports in the literature suggest that thymomas are chemosensitive tumors. Potential candidates for chemotherapy include approximately one third of the patients with an invasive thymoma that later metastasizes and all patients with stage IV disease. Fornasiero and colleagues reported successful cases and some long-term survivors following the administration of a regimen of cisplatin/vincristine/doxorubicin/cyclophosphamide for incompletely resected invasive thymomas or cases with unresectable disease.In 32 patients, a 47% complete and 90% overall response rate was noted with a median survival time of 15 months. A trial conducted by the European Organisation for Research and Treatment of Cancer reported that among 16 patients with recurrent or metastatic thymomas, 5 complete remissions and 4 partial remissions were observed. Median survival time of this more recent study was 4.3 years.Corticosteroids
Recently, case reports have documented the administration of oral glucocorticoids resulting in regression of an invasive thymoma. In one case, the patient showed complete regression to the thymoma and associated symptoms and has remained without radiological recurrence after 12 months.Multidisciplinary approach
A multidisciplinary approach to therapy for unresectable thymomas has been advocated. In one trial conducted by the M.D. Anderson Cancer Center, a treatment regimen consisting of induction chemotherapy (ie, 3 courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (ie, 3 courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone) was tested.
This study yielded encouraging results. Of 12 patients who underwent this treatment regimen, the disease had a complete response in 3 patients (25%), a partial response in 8 patients (67%), and a minor response in 1 patient (8%). Among 11 of these 12 patients (1 refused surgery), 9 (82%) had complete resections, and 2 (18%) who had been receiving radiation therapy and consolidation chemotherapy had incomplete resections. All 12 patients (100%) are alive at 7 years, and 10 of these patients (73%) are disease-free at 7 years. Therefore, the authors suggest that aggressive multimodal treatment is effective and may be curative in locally advanced, unresectable, malignant thymomas.
A study was conducted by Loehrer et al evaluating the effects of octreotide alone or with prednisone in 38 patients with advanced thymomas that expressed somatostatin receptors (ie, that were octreotide scan positive).The patients were given 0.5 mg subcutaneously 3 times daily. Four (10.5%) of the 38 patients had a partial response with octreotide treatment alone. In the 21 patients in whom prednisone (0.6 mg/kg daily) was added, 2 complete and 6 partial responses (38%) occurred. Combination therapy resulted in better progression-free survival than octreotide therapy alone. Octreotide therapy may be a valuable treatment to use in cases in which chemotherapy is ineffective.
Phone Numbers Reach Us -
India & International : +91 9371770341
Initial management in most cases of thymomas is surgical. Surgical excision provides the histological characteristics of the tumor and provides staging information that is helpful in determining the need for adjuvant therapy. Small and encapsulated thymomas are excised for diagnosis and treatment. In the past, obtaining a preoperative biopsy of large invasive thymomas was shunned for fear of local implantation of tumor cells. Currently, biopsies are performed for these atypical tumors to discover the histology of the tumor and to ascertain its invasive potential.
Recently, a single-institution retrospective study was conducted of 5 patients with stage IVA treated with pleuropneumonectomy. The median survival was 86 months, and the Kaplan-Meier survival was 75% at 5 years and 50% at 10 years. There were no operative mortalities in this study. It has been suggested that, in select patients, this approach after a complete resection and neoadjuvant chemotherapy may be promising.7
The prognosis of a person with a thymoma is based on the tumor's gross characteristics at operation, not the histological appearance. Benign tumors are noninvasive and encapsulated. Conversely, malignant tumors are defined by local invasion into the thymic capsule or surrounding tissue. The Masaoka staging system of thymomas is the most commonly accepted system. Although controversy exists pertaining to the use of postoperative radiation for invasive thymomas, the preponderance of evidence indicates that all thymomas, except completely encapsulated stage 1 tumors, benefit from adjuvant radiation therapy.
Preoperative adjuvant radiation therapy has been used to increase the possibility of complete resection when CT scan suggests a tumor is very large or invasive. Although doses of 30-45 gray (Gy) have been used in this approach, complete responses rarely have been reported. One caveat to this therapy is that the patient is placed at increased risk for radiation pneumonitis because of the large size of ports required to cover the field.
Patients with a preoperative diagnosis of MG and a thymoma should optimize their medical condition prior to surgery by using cholinesterase inhibitors and plasmapheresis if indicated.
Although the preferred approach is a median sternotomy providing adequate exposure of the mediastinal structures and allowing complete removal of the thymus, the cervical approach also is adequate. If the tumor is small and appears readily accessible, perform a total thymectomy with contiguous removal of mediastinal fat. If the tumor is invasive, perform a total thymectomy in addition to en bloc removal of involved pericardium, pleura, lung, phrenic nerve, innominate vein, or superior vena cava. Resect one phrenic nerve; however, if both phrenics are involved, do not resect either nerve, and debulk the area. Clip areas of close margins or residual disease to assist the radiation oncologist in treatment planning.
Controversy about whether biopsy versus subtotal excision is superior for treating unresectable tumors exists. Some studies have supported subtotal excision, while others have shown no difference between the 2 modalities. A generally accepted rule is that patients with invasive or residual disease should receive adjuvant therapy.
Postoperative Details Radiation therapy
Adjuvant radiation therapy in completely or incompletely resected stage III or IV thymomas is considered a standard of care. The use of postoperative radiation therapy in stage II thymomas has been more questionable. Thymomas are indolent tumors that may take at least 10 years to recur; therefore, short-term follow-up will not depict relapses accurately. Furthermore, the gross appearance of tumor invasiveness is subjective, depending on the opinion of the surgeon. In one report at Massachusetts General Hospital, 22% of patients (5 out of 23) with stage II disease developed recurrence, leading to a proposed recommendation that postoperative radiation be instituted in all patients with stage II thymoma.
In a study conducted by Curran and colleagues, of 21 patients with stage II and III disease who did not undergo postoperative (total resection) radiation therapy, 8 had recurrence in the mediastinum.The 5 patients who received adjuvant radiation did not have recurrences. A series from Memorial Sloan Kettering Cancer Center, however, showed that adjuvant radiation therapy did not improve survival or decrease recurrence in stage II and III disease.To reduce the incidence of local relapse, perform postoperative adjuvant radiation therapy in patients without completely encapsulated stage I tumors.
Relapse after primary therapy for a thymoma may occur after 10-20 years. Therefore, long-term follow-up probably should continue to be performed throughout the patient's life.
Complications (eg, radiation pericarditis, radiation pneumonitis, pulmonary fibrosis) following postoperative radiation therapy have been reported. Clinicians must consider carefully the risk versus benefit ratio of adjuvant radiation therapy because deaths from these complications have been reported.
Phone Numbers Reach Us -
India & International : +91 9371770341